| INTRODUCTION
Hematopoietic stem cell transplantation (SCT) has been increasingly used in pediatric patients to treat both malignant and non-malignant diseases. Advances in supportive care and techniques that prevent complications of SCT have allowed for treatment of a wider variety of diseases with improved outcomes. For supportive care, we have expanded our use of prophylactic antimicrobial therapy in this population. More targeted approaches to therapy, including decreased use of total body irradiation, have been implemented. Furthermore, improved skills in the care of critically ill pediatric patients have increased patient post-SCT survival. Regardless of these advances, pulmonary complications after SCT commonly occur and are a significant source of post-SCT morbidity and mortality.
Pulmonary complications after SCT have been estimated to occur in 40-60% of patients in adult studies, which can be separated into infectious and noninfectious etiologies. 1 In a recent pediatric study, noninfectious pulmonary complications were reported to occur in 28% of patients, and survival at 10 years was 76% in patients without early
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pulmonary complications in comparison to 18% in patients with early pulmonary complications. 2 Early complications were defined as those occurring within the first 100 days post-SCT. The predominant pulmonary complication observed was idiopathic pneumonia syndrome (IPS). Pleural effusion, pulmonary hemorrhage, reactive airway disease, bronchiectasis, and bronchiolitis obliterans were other noted pulmonary complications after SCT.
Furthermore, lung function abnormalities noted on pulmonary function tests (PFTs) have been documented in patients after SCT.
Decreased diffusion capacity is the most common abnormality identified, followed by restriction. Diffusion and restrictive impairments have been reported to improve with time. 3 Restriction often occurs with IPS and has been linked to acute graft-versus-host disease (GVHD). 4 Bronchiolitis obliterans, the most concerning pulmonary complication, causes progressive pulmonary compromise. Obstructive impairment as noted in bronchiolitis obliterans has been linked to chronic GVHD.
Previous studies have attempted to create models that predict pulmonary outcomes after SCT based on pre-SCT PFTs. A large adult study in 2005 demonstrated that a decrease in all lung function parameters pre-SCT was associated with a stepwise increase of developing early respiratory failure and death post-SCT. 5 This study also constructed a "Lung Function Score" (LFS), which correlated well with risk of early respiratory failure and death. The score was calculated using forced expiratory volume in one second (FEV 1 ) and diffusing capacity (DL CO ). In 2010, a similar study was completed in a smaller cohort of pediatric patients, and the LFS was validated in this population. 6 In spite of studies such as these, no scoring system for pulmonary risk is universally used in SCT patients prior to transplant.
Given the impact of pulmonary complications on survival, identifying patients who are at risk has the potential to impact prognosis and improve patient outcomes. However, using PFT data alone to predict post-SCT pulmonary complications provides only general knowledge of those who are at risk for pulmonary complications post-transplant. Increasingly, the desire for personalized medicine has driven evaluation of genetic variation in predicting disease outcomes. capacity was adjusted for hemoglobin (DL co ). All PFTs were normalized for age, gender, weight, and height using z-scores.
Available follow up PFTs were collected for the 49 patients.
Baseline, or pre-SCT, PFTs were obtained an average of 1 month, but no more than 2 months, prior to SCT. Seventeen patients died or were otherwise unable to complete follow-up PFTs. Thirty-one patients completed post-SCT PFTs at 1 year; one patient did not complete PFTs until 2 years post-SCT. Follow up PFTs at 2, 3, 4, and 5 years were also recorded, but were less consistently performed.
Based on a review of the current literature using Ovid, four SNPs were selected within the exomes of four distinct genes: rs1800629
(tumor necrosis factor α, or TNFα), rs1800871 (interleukin 10, or IL-10), rs1695 (glutathione-s-transferase P1, or GSTP1), and rs12477314
(Histone deacetylase 4, or HDAC4). Key phrases searched in the Ovid were "single nucleotide polymorphism," with either "pulmonary restriction" or "pulmonary obstruction." Articles that described specific SNPs in the exome were used. These SNPs were selected because they have been implicated in modifying severity of lung diseases which cause restriction and obstruction, such as asthma and α 1 -antitrypsin deficiency. [7] [8] [9] Each SNP has a known "ancestral allele," referred to as the "wild type" in animal models, which is the more common nucleotide found in the population. There is also a documented variant allele, which we refer to as the "minor allele."
Once SNPs were selected, each SNP was analyzed with three different models to ensure that the different combinations were all tested: a dominant model, a recessive model, and an additive model. In the dominant model, the group of individuals with two minor alleles was compared to a group of subjects having one or two of the ancestral alleles, considered the dominant group. In the recessive model, individuals with one or both minor alleles were grouped together, considered the recessive group, and compared to those having only ancestral alleles. In the additive model the number of minor alleles were treated as an ordinal outcome, with participants being categorized as having 0, 1, or 2 minor alleles.
ANOVA models were used to evaluate for associations between each SNP model and PFT outcomes as change from baseline to each follow-up time point. ANCOVA models were used to adjust for possible confounding variables: age, gender, and race. All analytic assumptions were verified and all analyses were performed using SAS v9.4 (SAS Institute, Cary, NC). Repeated measures analyses were not performed, due to low sample sizes at the later follow-up periods.
P values were corrected for multiple comparisons. Since four SNPs were assessed, the standard P-value of 0.05, which normally designates significance, was adjusted to 0.0125. Z-scores for spirometry were calculated with the SAS GLI macro, using the Global Lungs Initiative algorithms. 10,11 Z-scores for DL co and TLC were calculated using published references standards.
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| RESULTS
Using the recessive genetic model, patients who were homozygous for the ancestral allele of the glutathione-S-transferase P1 (GSTP1) SNP (rs1695) had a larger decline in FEV 1 (adjusted P-value < 0.01) and FEF 25-75 (adjusted P-value = 0.02) values at 1-year post-SCT compared to patients with one or two minor alleles (Fig. 1) . This association was not significant in subsequent post-SCT years. Using the adjusted Table 2) .
Death was divided into death from primary disease and transplant-related mortality. Neither death overall nor transplantrelated mortality were significantly associated with any of the SNPs using any genetic model. Of the patients included in this study cohort who died, the average time to death post-SCT was approximately 1 year (380 days).
| DISCUSSION
We report that patients who were homozygous for the ancestral allele of the GTSP1 SNP rs1695 had a greater decline in lung function at The four SNPs selected for this study were chosen because of previous reports demonstrating that they mediate severity of pulmonary disease after SCT or in other underlying etiologies known to cause restrictive and obstructive disease, such as asthma and Previously, TNFα was assessed in a study of cytokine expression in bronchoalveolar lavage samples from patients with pulmonary complications after SCT. 16 TNFα expression was demonstrated to be significantly increased in patients with both infectious and noninfectious pulmonary complications, and this elevation correlated with a poorer prognosis overall. IL-10 was demonstrated to be a genetic modifier for severity of chronic obstructive pulmonary disease (COPD)
in patients with α 1 -antitrypsin deficiency. 9 Finally, a preliminary study revealed that HDAC4 genetic variation may be associated with the development of asthma and COPD as patients age. 17 Although all three of these genes seemed like promising candidates for this study, none were shown to be significantly associated with PFT outcomes in our patient population.
As stated, Glutathione-S-transferase P1 (GSTP1) was significantly associated with lung function in our patient population. Glutathione-S-transferase is a superfamily of metabolic enzymes involved in the conjugation of reduced glutathione. 18 These reactions are generally considered detoxifying and protective from cytotoxic agents, but they have also been noted to create intermediate metabolites that are more toxic than their precursors. 19 In addition, these enzymes are known to metabolize chemotherapeutic agents and are often over expressed in tumors that are refractory to chemotherapy. GSTP1 is widely found in human epithelium, especially the lungs, esophagus, and placenta.
GSTP1 is most abundantly expressed in the alveoli, alveolar macrophages, and bronchioles and has been studied for its role in ameliorating the effects of air pollution, tobacco smoke, and α 1 -antitrypsin deficiency. 7, 8, 20 The SNP that we investigated within the GSTP1 gene is a substitution of adenosine (the ancestral allele) for guanine (the minor allele) at position 105. This leads to a missense mutation and causes the amino acid isoleucine to be replaced by valine. In a 2004 study in Taiwan, patients coding for isoleucine at this site were demonstrated to be at increased risk of developing asthma when exposed to air pollution. These findings correlate well with our results, demonstrating that the ancestral allele leads to diminished FEV 1 values and more airflow limitation in SCT patients 1 year post-transplant. In contrast, a 2006 publication reported a higher susceptibility to asthma in children who were exposed to tobacco smoke and had the minor allele, which codes for valine, at the 105 position. Though these are conflicting reports, they emphasize the importance of GSTP1 in modifying disease severity and demonstrate the need for further research into the mechanism of action of GSTP1.
In our study population, there was no correlation identified between GSTP1 and transplant-related mortality. The average time of death in this study, however, was around 1 year. This correlates chronologically with decrease in FEV 1 and FEF 25-75 related to GSTP1.
Given the fact that not all transplant-related mortality was secondary 5-year W/W (n = 0) n/a n/a n/a n/a n/a n/a Adj P-value n/a n/a n/a n/a n/a n/a
Values in bold indicate significant values.
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to pulmonary complications, it is not surprising that the two are not strongly correlated.
Further investigation of GSTP1 needs to be performed to assess its utility as a biomarker for pulmonary complications after SCT. In this study, patients with one or more minor allele for GSTP1 had better
PFTs 1-year post-SCT. One possible mechanism of action for this finding is that the minor allele leads to increased function of the GSTP1 gene; thereby, providing more protection against cytotoxic agents administered in preparation for and during SCT. Murine models have confirmed that the pro-inflammatory state following SCT leads to an increased production of reactive oxygen species. 21, 22 GSTP1 may be an important modulator of these effects after transplant.
Identifying best management approaches that decrease the morbidity and mortality of SCT is critical. Previous studies have suggested that depletion of T cells in the transplant itself provides protection against GVHD and subsequently, serious pulmonary complications. 23 This benefit must be weighed against the loss of important graft-versus-leukemia effects as well as the associated increased degree of immunosuppression and prolonged time to immune reconstitution when T cell depletion is performed. Newer therapies such as Alemtuzumab, or Campath, are being implemented to suppress T and B cells after SCT with fewer negative side effects than T cell depletion. 24 If GSTP1 genotype is validated as a marker for poor pulmonary outcomes, and patients are found to be at risk prior to transplant, the management of T and B cells pre-SCT and post-SCT is one of many areas of intervention.
Other possible strategies include reducing the intensity of the preparation used for transplant. Specifically, treatments known to have significant pulmonary side effects, such as busulfan and total body irradiation, could potentially be avoided. Finally, other tactics for decreasing pulmonary inflammation such as inhaled corticosteroids could be studied.
This pilot study has several limitations. The initial sample size of patients who underwent SCT during the given time period was larger than the selected population. As noted above, patients were excluded who did not undergo pre-SCT PFTs and exome SNP array PCR analysis. There were 25 patients who were too young to perform baseline PFTs and were excluded. Generally, the patients who did not perform baseline PFTS were those who were less than 5 years of age.
In patients who performed pre-SCT PFTs, follow up at 1 year was excellent unless the patient died or was too sick to perform PFTs.
Our sample size was too small to correct for confounders such as total body irradiation and chemotherapy received prior to SCT. In order to ameliorate this issue, each patient's PFT parameters were compared to his or her own personal baseline PFTs just prior to transplant. The change from baseline was compared between patients due to the variability in pulmonary impairment prior to SCT. However, due to the small sample size, a more restrictive change post-SCT in those homozygous for the ancestral allele of the GTSP1 SNP rs1695
may not have been fully delineated.
After correcting for multiple comparisons, the association between In comparison to the other three SNPS that were investigated in this study, GSTP1 stood out as an excellent candidate for further research in regards to SCT. As we move towards an era of personalized medicine in which genetic variation is widely assessed and applied clinically to patients, identifying genes becomes increasingly important. GSTP1 certainly merits further investigation.
